Tempus AI vs Becton Dickinson

Side-by-side comparison of AI visibility scores, market position, and capabilities

Becton Dickinson leads in AI visibility (79 vs 58)
Tempus AI logo

Tempus AI

ChallengerHealthcare Tech

Precision Medicine & Diagnostics

AI precision medicine company. NASDAQ: TEM. 2025 revenue $1.27B (+83% YoY). World's largest clinical/molecular data library. Founded 2015, Chicago. 2026 guidance ~$1.59B.

AI VisibilityBeta
Overall Score
C58
Category Rank
#142 of 596
AI Consensus
74%
Trend
up
Per Platform
ChatGPT
53
Perplexity
57
Gemini
55

About

Tempus AI is an AI-powered precision medicine company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. The company has built the world's largest library of clinical and molecular data, comprising over 40 million research records including 1.5 million with matched clinical-genomic data. Tempus provides precision medicine services across oncology, cardiology, radiology, and depression through Genomics, Data and Services, and AI Applications product lines.

Full profile
Becton Dickinson logo

Becton Dickinson

LeaderHealthcare Tech

Enterprise

Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.

AI VisibilityBeta
Overall Score
B79
Category Rank
#25 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
76
Perplexity
82
Gemini
84

About

Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.

Full profile

AI Visibility Head-to-Head

58
Overall Score
79
#142
Category Rank
#25
74
AI Consensus
77
up
Trend
stable
53
ChatGPT
76
57
Perplexity
82
55
Gemini
84
63
Claude
84
62
Grok
77

Key Details

Category
Precision Medicine & Diagnostics
Enterprise
Tier
Challenger
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Tempus AI
Precision Medicine & Diagnostics

Integrations

Only Tempus AI
Only Becton Dickinson
Tempus AI is classified as company. Becton Dickinson is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.